ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 26, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Apr 26, 2012
News
FDA Details Strategies for Addressing Globalization
By Patricia Van Arnum
A new report by FDA details the strategies, programs, and other activities the agency is using to address the rise of imported pharmaceutical products and APIs.
GSK Divests OTC Brands Worth $264.7 Million
By Stephanie Sutton
GlaxoSmithKline has reached an agreement to divest certain over-the-counter brands in selected territories to South Africa's Aspen Pharmacare Holdings for approximately $264.7 million.
FDA Reports Improvement in Postmarket Drug Oversight
By Susan Haigney
FDA highlights success of CDER's drug-monitoring program.
Merck KGaA Announces Job Cuts
By Stephanie Sutton
Merck KGaA has revealed further details about its previously announced restructuring program, including plans to eliminate approximately 580 jobs.
EC Offers Cash Prize for Vaccine Stability
By Stephanie Sutton
The European Commission is offering a EUR 2-million ($2.64 million) inducement prize to encourage innovation in the area of cold-chain logistics and vaccine stability.
Week of Apr. 23, 2012: AstraZeneca to Acquire Ardea Biosciences; Pfizer to Divest Nutrition Business to Nestlé; and More
AstraZeneca to Acquire Ardea Biosciences; Pfizer to Divest Nutrition Business to Nestlé; and More.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here